Sisaf Ltd. has entered into a collaboration with the University of Leipzig to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.
Praetego Inc. has been granted a US$300,000 phase I Small Business Technology Transfer Research (STTR) award by the National Eye Institute (NEI) to advance the company's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.
Tevard Biosciences Inc. has entered into a 4-year global research collaboration with Vertex Pharmaceuticals Inc. aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD) caused by nonsense mutations, with options to expand into additional muscular dystrophies and a second indication.
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has signed a new sponsored research agreement (SRA) with the Vaccine and Immunotherapy Center at Massachusetts General Hospital (MGH), Harvard Medical School to initiate a preclinical immuno-oncology study targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers.
Lift Biosciences Ltd. and Minaris Regenerative Medicine GmbH have entered into a development and manufacturing partnership for N-Lift, Lift's first-in-class neutrophil progenitor-based leukocyte infusion therapy for the treatment of various cancer indications, including pancreatic cancer, lung cancer and other solid tumors.
Hookipa Pharma Inc. has achieved a US$10 million milestone payment under its collaboration agreement with Roche (F. Hoffmann-La Roche Ltd.) to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers.
UC Davis Comprehensive Cancer Center is partnering with Targagenix Inc. and Northeastern University to study pancreatic ductal adenocarcinoma (PDAC). The partnership will receive nearly US$3 million over 5 years through funding from the National Institutes of Health (NIH).
Atreca Inc. and Xencor Inc. have mutually selected the first program from their strategic collaboration combining an Atreca-discovered antibody with Xencor's Xmab bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).
RSS
